Trung Huynh
Stock Analyst at UBS
(4.82)
# 82
Out of 5,090 analysts
56
Total ratings
72.97%
Success rate
32.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $595 → $660 | $727.50 | -9.28% | 5 | Nov 7, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $895 → $1,080 | $1,019.00 | +5.99% | 10 | Nov 7, 2025 | |
| INSM Insmed | Maintains: Buy | $194 → $223 | $204.68 | +8.95% | 9 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $1.82 | +1,273.63% | 3 | Aug 15, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $334.09 | -5.12% | 6 | Aug 6, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $29.10 | +30.58% | 2 | May 9, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $25.89 | -3.44% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $52.35 | +3.15% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $2.69 | +160.22% | 2 | Apr 1, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $7.91 | +64.35% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $201.68 | -13.23% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $100.84 | +24.95% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $225.62 | -24.65% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.95 | - | 1 | Mar 23, 2021 |
Regeneron Pharmaceuticals
Nov 7, 2025
Maintains: Neutral
Price Target: $595 → $660
Current: $727.50
Upside: -9.28%
Eli Lilly and Company
Nov 7, 2025
Maintains: Buy
Price Target: $895 → $1,080
Current: $1,019.00
Upside: +5.99%
Insmed
Oct 31, 2025
Maintains: Buy
Price Target: $194 → $223
Current: $204.68
Upside: +8.95%
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $1.82
Upside: +1,273.63%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $334.09
Upside: -5.12%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $29.10
Upside: +30.58%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $25.89
Upside: -3.44%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $52.35
Upside: +3.15%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $2.69
Upside: +160.22%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $7.91
Upside: +64.35%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $201.68
Upside: -13.23%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $100.84
Upside: +24.95%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $225.62
Upside: -24.65%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $8.95
Upside: -